182 related articles for article (PubMed ID: 36576731)
1. Investigating the Role of DUSP4 in Uveal Melanoma.
Aughton K; Sabat-Pospiech D; Barlow S; Coupland SE; Kalirai H
Transl Vis Sci Technol; 2022 Dec; 11(12):13. PubMed ID: 36576731
[TBL] [Abstract][Full Text] [Related]
2. Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Gupta A; Towers C; Willenbrock F; Brant R; Hodgson DR; Sharpe A; Smith P; Cutts A; Schuh A; Asher R; Myers K; Love S; Collins L; Wise A; Middleton MR; Macaulay VM
Br J Cancer; 2020 Feb; 122(4):506-516. PubMed ID: 31839677
[TBL] [Abstract][Full Text] [Related]
3. DUSP4 Inactivation Leads to Reduced Extracellular Signal‒Regulated Kinase Activity through Upregulation of DUSP6 in Melanoma Cells.
Kamada H; Yasuhira S; Shibazaki M; Amano H; Maesawa C
J Invest Dermatol; 2022 Sep; 142(9):2499-2507.e6. PubMed ID: 35189148
[TBL] [Abstract][Full Text] [Related]
4. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.
Mazumdar A; Poage GM; Shepherd J; Tsimelzon A; Hartman ZC; Den Hollander P; Hill J; Zhang Y; Chang J; Hilsenbeck SG; Fuqua S; Kent Osborne C; Mills GB; Brown PH
Breast Cancer Res Treat; 2016 Aug; 158(3):441-54. PubMed ID: 27393618
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.
Liu Y; Du F; Chen W; Yao M; Lv K; Fu P
Exp Cell Res; 2013 Dec; 319(20):3140-9. PubMed ID: 24012960
[TBL] [Abstract][Full Text] [Related]
6. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
Gröschl B; Bettstetter M; Giedl C; Woenckhaus M; Edmonston T; Hofstädter F; Dietmaier W
Int J Cancer; 2013 Apr; 132(7):1537-46. PubMed ID: 22965873
[TBL] [Abstract][Full Text] [Related]
7. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
Jung HH; Lee SH; Kim JY; Ahn JS; Park YH; Im YH
Sci Rep; 2016 Sep; 6():33035. PubMed ID: 27604655
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Uveal Melanoma Cell Lines and Primary Tumor Samples in 3D Culture.
Aughton K; Shahidipour H; Djirackor L; Coupland SE; Kalirai H
Transl Vis Sci Technol; 2020 Jun; 9(7):39. PubMed ID: 32832244
[TBL] [Abstract][Full Text] [Related]
9. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
10. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Balko JM; Cook RS; Vaught DB; Kuba MG; Miller TW; Bhola NE; Sanders ME; Granja-Ingram NM; Smith JJ; Meszoely IM; Salter J; Dowsett M; Stemke-Hale K; González-Angulo AM; Mills GB; Pinto JA; Gómez HL; Arteaga CL
Nat Med; 2012 Jul; 18(7):1052-9. PubMed ID: 22683778
[TBL] [Abstract][Full Text] [Related]
11. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
12. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
[TBL] [Abstract][Full Text] [Related]
14. Redox activation of DUSP4 by N-acetylcysteine protects endothelial cells from Cd²⁺-induced apoptosis.
Barajas-Espinosa A; Basye A; Jesse E; Yan H; Quan D; Chen CA
Free Radic Biol Med; 2014 Sep; 74():188-199. PubMed ID: 24973647
[TBL] [Abstract][Full Text] [Related]
15. DUSP4 is involved in the enhanced proliferation and survival of DUSP4-overexpressing cancer cells.
Ratsada P; Hijiya N; Hidano S; Tsukamoto Y; Nakada C; Uchida T; Kobayashi T; Moriyama M
Biochem Biophys Res Commun; 2020 Jul; 528(3):586-593. PubMed ID: 32505357
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling.
Britson JS; Barton F; Balko JM; Black EP
Biochem Biophys Res Commun; 2009 Dec; 390(3):849-54. PubMed ID: 19836351
[TBL] [Abstract][Full Text] [Related]
17. Impaired Dual-Specificity Protein Phosphatase DUSP4 Reduces Corticosteroid Sensitivity.
Kobayashi Y; Ito K; Kanda A; Tomoda K; Mercado N; Barnes PJ
Mol Pharmacol; 2017 May; 91(5):475-481. PubMed ID: 28283554
[TBL] [Abstract][Full Text] [Related]
18. Analysis of CRISPR-Cas9 screens identifies genetic dependencies in melanoma.
Christodoulou E; Rashid M; Pacini C; Droop A; Robertson H; Groningen TV; Teunisse AFAS; Iorio F; Jochemsen AG; Adams DJ; Doorn RV
Pigment Cell Melanoma Res; 2021 Jan; 34(1):122-131. PubMed ID: 32767816
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition.
Cagnol S; Rivard N
Oncogene; 2013 Jan; 32(5):564-76. PubMed ID: 22430215
[TBL] [Abstract][Full Text] [Related]
20. DUSP4 appears to be a highly localized endogenous inhibitor of epileptic signaling in human neocortex.
Kirchner A; Bagla S; Dachet F; Loeb JA
Neurobiol Dis; 2020 Nov; 145():105073. PubMed ID: 32890776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
